Cabergoline vs Bromocriptine for High Prolactin

The Endocrine Society prefers cabergoline over bromocriptine for most people with a prolactinoma because cabergoline normalizes prolactin more often and produces more frequent tumor shrinkage.¹ Cabergoline also caused fewer treatment withdrawals in the main head-to-head trial, although that trial enrolled women.² Your choice can change based on the cause of your high prolactin, tumor size, side effects, resistance, contraindications, and cost.

Both Dopamine Agonists Side by Side

Cabergoline and bromocriptine are dopamine agonists, which means they activate dopamine receptors that reduce prolactin secretion. Both drugs are ergot derivatives.

Cabergoline is approved for hyperprolactinemic disorders caused by a pituitary adenoma or an unknown cause.³ Parlodel, a bromocriptine product, is approved for conditions associated with high prolactin, including hypogonadism and prolactin-secreting adenomas. Parlodel is also approved for acromegaly and Parkinson’s disease.⁴

Drug	Dosing Frequency	Prolactin Normalization in Head-to-Head Trials	Tolerability and Withdrawals for Side Effects	Heart-Valve Risk	Other Approved Uses
Cabergoline	Set by the prescriber for each patient.	Stable normal prolactin in 83% over the full trial; normal prolactin in 77% at 8 weeks. Both figures came from women with hyperprolactinemic amenorrhea.2,3	Adverse effects in 68%; 3% stopped because of intolerance over the full trial. Nausea affected 29% during the 8-week double-blind period.2,3	Valve disease is listed in the label. Risk appears related to exposure, and monitoring guidance differs between the US label and a UK position statement.1,3,11	None beyond hyperprolactinemic disorders in the cabergoline label.3
Bromocriptine	Set by the prescriber for each patient.	Stable normal prolactin in 59% over the full trial; normal prolactin in 59% at 8 weeks. Both figures came from women with hyperprolactinemic amenorrhea.2,3	Adverse effects in 78%; 12% stopped because of intolerance over the full trial. Nausea affected 43% during the 8-week double-blind period.2,3	Bromocriptine is also an ergot derivative, and its label includes cardiac-valve fibrosis among reported adverse reactions. Comparative risk at prolactin-treatment exposures has not been established.4	Parlodel is approved for acromegaly and Parkinson’s disease. Cycloset, a different bromocriptine product, is approved for glycemic control in adults with type 2 diabetes.4,5
Evidence-Based Verdict	Cabergoline is generally preferred when both drugs are suitable.	Cabergoline performed better in the comparative evidence.1,2,6	Cabergoline was better tolerated in the main trial.2	Your cardiac history and planned exposure affect monitoring.	Bromocriptine remains an approved option when cost, tolerance, or another clinical factor changes the choice.1,4

The 83% and 59% figures measure stable prolactin normalization across the full study. The 77% and 59% figures describe normal prolactin at eight weeks. Compare each figure with its partner from the same window: 83% against 59% over the full trial, and 77% against 59% at eight weeks.^2,3

The Head-to-Head Evidence

The main comparative trial found higher prolactin normalization and fewer treatment withdrawals with cabergoline. The double-blind trial enrolled 459 women with hyperprolactinemic amenorrhea, so its numbers do not directly establish outcomes for men.²

Across the full trial, 83% of women receiving cabergoline achieved stable normal prolactin compared with 59% receiving bromocriptine. Adverse effects occurred in 68% and 78%, respectively. Treatment intolerance led 3% of the cabergoline group and 12% of the bromocriptine group to stop.²

A meta-analysis of four publications also favored cabergoline for prolactin normalization. Bromocriptine produced more adverse effects across the included randomized trials.⁶ Some pooled outcomes involved menstruation and ovulation, so they cannot answer whether cabergoline produces better testosterone or sexual outcomes in men.

The Endocrine Society guideline gives cabergoline preference because it normalizes prolactin more often and produces more frequent pituitary tumor shrinkage.¹ The guideline reports resistance in about 10% of people treated with cabergoline and 25% treated with bromocriptine. It recommends switching to cabergoline when bromocriptine does not control the condition.¹

High Prolactin in a Man’s Testosterone Workup

High prolactin can suppress gonadal function and contribute to low testosterone, infertility, low libido, and erectile dysfunction.¹ This is why prolactin may appear in your evaluation when low testosterone or low libido is the symptom that first brings you to a physician.

A small 1978 series examined 22 men with prolactin-secreting pituitary tumors and hypogonadism. Twenty reported impotence. Among 13 men treated with bromocriptine, prolactin fell in all 13 and testosterone rose in nine.⁷ The study was small and cannot predict your response, but it shows why treating the source of elevated prolactin can matter during a testosterone workup.

Two men in that series experienced improved potency only after bromocriptine was added to prior testosterone treatment.⁷ That observation cannot support a general treatment rule. It does show why a physician reads testosterone and prolactin together.

Your prolactin result needs context. A physician will consider symptoms, repeat measurements, medications, other hormone results, and pituitary imaging when indicated.

One high prolactin result is a data point. The repeat result and the rest of your hormone panel show whether it is part of a pattern that could connect to testosterone and libido.

Comparative Side Effects

Cabergoline and bromocriptine can both cause nausea, headache, and dizziness. Cabergoline produced less nausea in the eight-week double-blind period of the comparative trial in women, with rates of 29% for cabergoline and 43% for bromocriptine. Dizziness rates were similar at 17% and 18%.³

The Parlodel label reports nausea as its most frequent adverse effect in hyperprolactinemic conditions. It also lists headache, dizziness, fatigue, vomiting, abdominal cramps, and drowsiness.⁴ Your prescriber should review whether symptoms began after treatment and whether they interfere with daily activity.

Both labels warn about impulse-control disorders, which are compulsive behaviors such as uncontrolled gambling, spending, sexual activity, or repetitive actions.^3,4 A case-control survey found more impulse-control disorders among men with dopamine agonist-treated prolactinomas than among men with nonfunctioning pituitary adenomas who had no dopamine agonist exposure.⁸ The survey was small and does not provide a precise risk for you.

Restored libido can follow successful treatment of high prolactin. Compulsive sexual urges are different. If sexual behavior feels new, intense, or difficult to control, tell your prescriber rather than assuming the change is part of recovery.

The full cabergoline guide for men covers its adverse effects in more depth.

Heart-Valve Monitoring

Heart-valve concerns around cabergoline came largely from Parkinson’s disease studies that involved much higher exposure than treatment for high prolactin. Two 2007 studies found more valve regurgitation among people taking cabergoline for Parkinson’s disease, with greater cumulative exposure linked to more severe findings.^9,10 Those results do not establish the same risk during treatment for hyperprolactinemia.

A joint UK position statement found very limited evidence of clinically meaningful valve disease at exposures used for hyperprolactinemia. It recommends an echocardiogram before treatment and repeat monitoring that scales with exposure.¹¹

The current US cabergoline label uses stricter language. It calls for a cardiovascular evaluation with an echocardiogram before treatment, followed by repeat echocardiography every 6 to 12 months or when symptoms warrant it.³ The label also reports valvulopathy cases in people who received lower doses for hyperprolactinemic disorders.³ It also contraindicates cabergoline in people with anatomical evidence of valve disease and certain fibrotic disorders.

Bromocriptine should not be treated as free of this concern. Its label includes cardiac-valve fibrosis among reported adverse reactions and retroperitoneal fibrosis with long-term, high-exposure treatment.⁴ Your physician should use the drug label, your medical history, physical examination, and imaging to set an appropriate monitoring plan.

Choosing Between the Two Drugs

Cabergoline is the usual first choice when the goal is to normalize prolactin and shrink a prolactinoma. The comparative trial, meta-analysis, and Endocrine Society guideline point in the same direction.^1,2,6

Lowering prolactin treats the elevated result. Your physician still needs to identify why it is high and how it relates to testosterone, libido, and the rest of your hormone results.

Bromocriptine remains a reasonable approved treatment. The Endocrine Society guideline states that its cabergoline preference gives less weight to treatment cost and more weight to convenience and reversal of hypogonadism.¹ The guideline does not provide a price comparison.

Cabergoline may be a poor fit if you have a listed contraindication, cannot tolerate it, or remain resistant to treatment. Bromocriptine may also be unsuitable because of side effects, contraindications, or failure to control prolactin. Your prescriber should choose between them after reviewing the cause of the elevation, tumor findings, symptoms, treatment response, and the other medications you take.

Treatment Monitoring and Withdrawal

Monitoring usually includes prolactin measurements, symptom review, medication tolerance, and pituitary magnetic resonance imaging (MRI) when a tumor is present or prolactin rises. Cardiac monitoring is also part of cabergoline treatment under the current US label.^1,3

Your physician reads each follow-up prolactin result as part of a trend and alongside the rest of your hormone panel.

Impulse-control symptoms deserve direct questions because you may not immediately recognize them as a medication effect. Your physician may ask about gambling, spending, eating, libido, and other urges during follow-up.^3,4

The Endocrine Society suggests that tapering or withdrawal may be considered after at least two years when prolactin is normal and MRI shows no visible tumor remnant. This is a weak recommendation supported by very low-quality evidence. It does not mean treatment automatically ends after two years.¹

Recurrence after withdrawal ranged from 26% to 69% in the studies reviewed by the guideline.¹ A separate observational study found recurrence rates of 24% for nontumoral hyperprolactinemia, 31% for microprolactinomas, and 36% for macroprolactinomas two to five years after carefully selected patients stopped cabergoline.¹²

If treatment is withdrawn, the guideline recommends regular prolactin testing and repeat MRI when prolactin rises above normal.¹ Your physician should decide whether withdrawal fits your laboratory trend and MRI findings, then continue surveillance.

The Opt Take on Cabergoline and Bromocriptine

When prolactin is high, an Opt Health physician reads it alongside total and free testosterone and the rest of your hormone panel. The aim is to understand how the result fits your libido, sexual function, medications, symptoms, and health history before deciding the next step.

The process starts with a panel of 55+ biomarkers and a 1:1 physician review. One elevated prolactin value is read in context with repeat measurements and related hormone results. The physician then decides whether the result calls for continued monitoring, another evaluation, or referral to a specialist. Cabergoline or bromocriptine is never treated as an automatic answer to one number.

Labs and a physician consultation repeat every 3 to 4 months. Your physician can review the prolactin trend alongside total and free testosterone, symptoms, treatment tolerance, and any specialist findings. The plan can then change based on what the follow-up shows.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.